Hi [[ session.user.profile.firstName ]]

Preanalytics impacts your results

How can ischemia impact your assay results? Watch this video and see...
Recorded Mar 31 2015 3 mins
Your place is confirmed,
we'll send you email reminders
Presented by
CDx Insights
Presentation preview: Preanalytics impacts your results

Network with like-minded attendees

  • [[ session.user.profile.displayName ]]
    Add a photo
    • [[ session.user.profile.displayName ]]
    • [[ session.user.profile.jobTitle ]]
    • [[ session.user.profile.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
  • [[ card.displayName ]]
    • [[ card.displayName ]]
    • [[ card.jobTitle ]]
    • [[ card.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(card) ]]
  • Channel
  • Channel profile
  • Predictive assays: Analytic validation, clinical validation and clinical utility Recorded: Aug 25 2016 55 mins
    Krista Acosta, Nicole Schechter, PSM, PMP, Al Yates, PhD
    Predictive assays are a key element of personalized healthcare because these assays aid physicians in selecting individuals who are most likely or least likely to benefit from specific therapies. In addition to analytical validation, predictive assays require clinical validation to establish their clinical utility. Krista Acosta, Manager, CDx Pharma Services Assay Development, Nicole Schechter, PSM, PMP, CDx Director, Project Leader and Alton Yates PhD, Senior Manager, Clinical Sciences Management, will address the development and performance differences between predictive assays developed under in vitro diagnostic regulations and laboratory developed tests.
  • The dangers of using a laboratory developed test as a companion diagnostic Recorded: Jun 1 2016 51 mins
    Keith Miller, FIBMS, Director, UKNEQAS-ICC&ISH
    Companion diagnostic tests are most commonly used to determine patient eligibility for specific therapies and are designed to ensure the therapy is administered safely to patients who are most likely to benefit. Thus, companion diagnostic tests are crucial in facilitating personalized healthcare for the individual patient. Join us as Keith Miller, FIBMS, Director of the United Kingdom National External Quality Assessment Scheme for Immunohistochemistry and In Situ Hybridisation (UKNEQAS-ICC&ISH), addresses the inherent risks in using laboratory developed tests as companion diagnostics, and the role of external quality assessment schemes (EQA) in helping laboratories monitor and maintain quality testing.
  • Personalized Healthcare in Oncology: Past, Present and Future Recorded: Feb 25 2016 60 mins
    Eric Walk MD, FCAP, Chief Medical Officer, Ventana Medical Systems, Inc.
    Personalized healthcare continues to evolve. There are now five pillars of cancer therapy and two of the five, targeted therapies and immunotherapy, are personalized approaches. Join us at 9 AM MST, February 25, 2016 as Eric Walk MD, FCAP, Chief Medical Officer, Ventana Medical Systems, Inc. (Ventana), addresses how personalized healthcare has evolved and impacted cancer diagnosis and therapy.
  • Companion diagnostics and targeted therapies: requirements for success Recorded: Dec 1 2015 59 mins
    Abigail McElhinny PhD, Ventana Medical Systems Inc., and Steffan Ho, MD, PhD, Pfizer Inc.
    Propelled by the need to personalize medical care, more and more targeted therapies and companion diagnostics are being developed. What are the key considerations for successful co-development of companion diagnostics and targeted therapies? Join Abigail McElhinny PhD, Vice President Development, Ventana Medical Systems Inc., and Steffan Ho, MD, PhD, Executive Director, Early Development, Translational and Immuno-Oncology, Pfizer Oncology, Pfizer Inc., on November 12, 2015, 9 AM Phoenix time as they address biological, development, regulatory, and other considerations that are indispensable for success.
  • Lung cancer: companion diagnostics and emerging markers Recorded: Sep 23 2015 57 mins
    Peter Bela Illei, M.D., Assistant Professor of Pathology and Oncology, Johns Hopkins Medicine
    Lung cancer is the number one cancer globally and the leading cause of cancer related deaths. Join Peter Bela Illei, M.D., Assistant Professor of Pathology and Oncology, Johns Hopkins Medicine on September 23 at 9 AM MST, he will address the key challenges and considerations for effectively managing lung cancer testing now and in the future.
  • Is NGS the universal companion diagnostic? Recorded: May 26 2015 60 mins
    James Hnatyszyn, PhD, Senior Director, Companion Diagnostics, Global Laboratory Operations, Ventana Medical Systems Inc.
    Yes? No? Maybe? Join Dr. James Hnatyszyn on May 26 at 9 AM, Phoenix time to learn more about the impact of NGS on research and clinical diagnostics. Dr. Hnatyszyn is the Senior Director, Companion Diagnostics, Global Laboratory Operations at Ventana Medical Systems Inc. He will review the available NGS technologies and address key issues to consider when using these technologies.
  • Ischemia, fixation, assay results, and information transfer: novel approaches Recorded: Mar 31 2015 58 mins
    Dr. Geoffrey Baird, University of Washington, Dr. David Chafin, Ventana Medical Systems Inc.
    How do ischemia and fixation impact the quality of your assay results and information transfer? Garbage in! Garbage out! Join Geoffrey Baird MD, PhD and David Chafin, PhD at 9 AM Mountain Time, March 31, 2015, who will discuss the impact of ischemia and fixation on assay results, information transfer and some novel approaches to address these important factors. Dr. Baird is an Assistant Professor of Laboratory Medicine and an Adjunct Assistant Professor of Pathology at the University of Washington. Dr. Chafin is a Principle Scientist, Technology and Applied Research at Ventana Medical Systems Inc.
  • Preanalytics impacts your results Recorded: Mar 31 2015 3 mins
    CDx Insights
    How can ischemia impact your assay results? Watch this video and see...
  • Cancer in Context—The Unique Role of IHC Companion Diagnostics Recorded: Jan 22 2015 41 mins
    Dr. Mary Padilla, Pathologist, Senior Medical Director, Companion Diagnostics, Ventana Medical Systems Inc
    With the advent of NGS and existing molecular approaches, why is IHC unique and relevant for companion diagnostics? January 22, 2015 to learn more from Dr. Mary Padilla, Pathologist, Senior Medical Director, Companion Diagnostics, Ventana Medical Systems Inc. If you provide companion diagnostic services, develop targeted therapies, or prescribe targeted therapies, then this is the webinar for you!
  • Protein Power: IHC and Companion Diagnostics Recorded: Jan 9 2015 6 mins
    Dr. Peter Banks, Sr. Pathologist, Global Scientific Affairs, Ventana Medical Systems, Inc.
    Why is IHC a useful and essential tool for companion diagnostics? Listen to the perspective of Dr. Peter Banks, an international recognized diagnostic pathologist, the former President Society for Hematopathology, and a founding member International Lymphoma Study Group.
CDx Insights
Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA products are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to help reduce errors, support diagnosis and enable informed treatment decisions by anatomic pathology professionals. VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of companion diagnostics to identify the patients most likely to respond favorably to specific therapies.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Preanalytics impacts your results
  • Live at: Mar 31 2015 12:05 am
  • Presented by: CDx Insights
  • From:
Your email has been sent.
or close